
Imaflex Inc.
IFX.VTSXVConsumer Cyclical
$2.34
+$0.00(+0.00%)
Market Cap$121887411
P/E Ratio—
52W High$2.34
52W Low$1
Imaflex Inc.(IFX.V)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · IFX.V · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.09B | $0.11B | $0.11B | $0.09B |
| Cost of Revenue | $0.09B | $0.08B | $0.09B | $0.09B | $0.07B |
| Gross Profit | $0.02B | $0.01B | $0.02B | $0.02B | $0.02B |
| Gross Margin %(computed) | 16.35% | 11.76% | 16.18% | 16.19% | 19.11% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Operating Income | $0.01B | $0.00B | $0.01B | $0.01B | $0.01B |
| Operating Margin %(computed) | 7.08% | 3.17% | 8.96% | 9.65% | 10.72% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.01B | $0.00B | $0.01B | $0.01B | $0.01B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.01B | $0.00B | $0.01B | $0.01B | $0.01B |
| Net Margin %(computed) | 6.79% | 0.54% | 8.18% | 7.78% | 7.32% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.14 | $0.01 | $0.18 | $0.17 | $0.13 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.01B | $0.01B | $0.02B | $0.01B | $0.01B |
| EBITDA Margin %(computed) | 13.15% | 6.43% | 14.00% | 13.20% | 14.86% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · CAD · B
深入了解Imaflex Inc.
关于Imaflex Inc.(IFX.V)损益表
Imaflex Inc.(IFX.V)损益表数据来源于SEC Form 10-K及10-Q申报文件。2024财年,IFX.V实现营收$0.11B,毛利润$0.02B(毛利率16.35%),净利润$0.01B(净利率6.79%)。
常见问题
IFX.V · 4 问Imaflex Inc.(IFX.V)2024财年营收为$0.11B,同比up17.4%。
IFX.V revenueIFX.V salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08